Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 304 Records) |
| Query Trace: Neoplasms and DCR[original query] |
|---|
| Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2024 9 36 (4): 398-409. Shouzheng Wang, Jiayu Liu, Yan Wang, Ying Hu, Ziling Liu, Yu Yao, Li Liang, Yutao Liu, Lin Wang, Junling Li, Puyuan Xi |
| Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment. American journal of clinical oncology 2024 9 . Zaheer Qureshi, Faryal Altaf, Abdur Jamil, Rimsha Siddiq |
| Immune checkpoint inhibitors for patients with mismatch-repair deficient or microsatellite instability-high advanced cancers: a meta-analysis of phase I-III clinical trials. International journal of surgery (London, England) 2024 8 . Wei Wang, Zubing Mei, Yajie Chen, Jian Jiang, Yanli Qu, Keyoumu Saifuding, Ning Zhou, Gilisihan Bulibu, Yong Tang, Xinyu Zhai, Zhi Jia |
| A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib. Therapeutic advances in medical oncology 2024 8 16 17588359241264730. Yongfeng Yu, Wen Dong, Yanxia Shi, Rong Wu, Qitao Yu, Feng Ye, Chengzhi Zhou, Xiaorong Dong, Xingya Li, Yongsheng Li, Zhen Li, Lin Wu, Yueyin Pan, Hong Shen, Dehua Wu, Zhongyuan Xu, Jinsheng Wu, Nong Xu, Yanru Qin, Aimin Zang, Jingdong Zhang, Jianya Zhou, Xiaotao Zhang, Yanqiu Zhao, Fugen Li, Huizhen Wang, Qi Liu, Zhenyong Han, Jin Li, Shun |
| Pulmonary adenocarcinoma with enteric differentiation (PAED) without TTF-1 expression is a very rare subtype with limited treatment options and poor prognosis. Oncology 2024 8 . Franziska Maria Kraus, Alexander Traut, Georg Nilius, Jan Volmerig, Andreas Koziorowski, Imke Stöver, Florian Grabellus, Michael Stahl, Daniel C Christo |
| Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis. Heliyon 2024 8 10 (14): e34626. Zhongsheng Peng, Kaibo Ding, Mingying Xie, Yanjun |
| [The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2024 7 46 (7): 696-702. M Yang, J J Wang, S Q Deng, S S Liang, L S |
| Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. European journal of cancer (Oxford, England : 1990) 2024 7 208 114204. Maximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, Enric Carcereny, Christophe Dooms, Se-Hoon Lee, Eva Morocz, Terufumi Kato, Tudor-Eliade Ciuleanu, Grace K Dy, Barbara Parente, Kenneth J O'Byrne, Quincy S Chu, Gilberto De Castro Junior, Nicolas Girard, Wendy Snyder, Qui Tran, William Kormany, Brett Houk, Bhakti Mehta, Alessandra Curioni-Fonteced |
| Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. Journal of immunotherapy (Hagerstown, Md. : 1997) 2024 7 . James Yu, Robin Park, Ruoyu Miao, Iman Imanirad, Moazzam Shahzad, Jose M Laborde, Todd C Knepper, Christine M Walko, Richard K |
| A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer. Journal of thoracic disease 2024 7 16 (6): 3782-3793. Christine Auberle, Feng Gao, Mark Sloan, Daniel Morgensztern, Linda Winkler, Jeffrey P Ward, Siddhartha Devarakonda, Timothy P Rearden, Ramaswamy Govindan, Saiama N Waq |
| Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2024 6 . Julien Hoba, Adrien Grancher, Vincent Hautefeuille, Anthony Turpin, Karine Bouhier-Leporrier, Marie-Pierre Galais, Anne-Laure Bignon, Aude Di Fiore, Romain Desgrippes, Laurent Miglianico, Benoit Avisse, Mathieu Baconnier, You-Heng Lam, Marie Dutherage, David Sefrioui, Karine Le Malicot, Jean-Marc Phelip, Pierre Michel, André Gillibert, Frédéric Di Fio |
| Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib. Frontiers in oncology 2024 6 14 1405683. Huixian Zhang, Ziheng Zhang, Ningning Yan, Xingya |
| Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis. Endocrine 2024 5 . Jonathan N Priantti, Natasha Maranhão Vieira Rodrigues, Francisco Cezar Aquino de Moraes, Allyson Guimarães da Costa, Deborah Laredo Jezini, Maria Izabel Ovellar Heckma |
| Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis. Journal of gastrointestinal oncology 2024 5 15 (2): 689-709. Linhui Zhu, Xuan Ye, Youjun She, Wensheng Liu, Kiyoshi Hasegawa, Roberta Elisa Rossi, Qiong Du, Qing Zh |
| Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18. Translational lung cancer research 2024 5 13 (4): 875-884. Yuanyuan Zhang, Hao Zeng, Chang Qi, Sihan Tan, Qin Huang, Xin Pu, Kenichi Suda, Mariacarmela Santarpia, Panwen Tian, Yalun |
| DNA Checkpoint Gene Mutation as a Biomarker for Immune Checkpoint Inhibitor Therapy in Advanced Biliary Tract Cancer. Anticancer research 2024 4 44 (5): 2103-2108. Ji Eun Shin, Seung Tae K |
| Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer. Frontiers in pharmacology 2024 4 15 1331138. Xiaojuan Zhang, Mina Zhang, Xinyang Du, Guowei Zhang, Yuanyuan Niu, Chunhua Wei, Lanwei Guo, Chao Shi, Hangfan Liu, Huijuan Wa |
| Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 4 . Ke Wang, Manyi Xu, Yanhua Wang, Chunwei Xu, Yue Hao, Zhengbo So |
| Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 4 . Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo So |
| Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53. Lung cancer (Amsterdam, Netherlands) 2024 12 199 108068. Mingying Wu, Na Zhou, Mei Guan, Yingyi Wang, Yuzhou Wa |
| Real-world efficacy and safety of combined first-line treatment with PARP inhibitors and novel hormonal therapy in mCRPC patients with HRR gene mutations. Frontiers in genetics 2024 12 15 1505163. Andong Guo, Chenrui Wu, Jishuang Cao, Kejia Zhu, Sentai Di |
| Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO precision oncology 2024 11 8 e2400331. Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, Isabella Michelon, Caio Castro, Natasha B Leighl, Ludimila Cavalcante, Alfredo Addeo, Jair Bar, Nobuyuki Horita, Alessio Cortellini, Amin H Nassar, Maysa Vilbert, Abdul Rafeh Naqa |
| A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 10 JCO2400533. Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn, Catherine A Shu, Chul Kim, Mary Jo Fidler, Richard Hall, Yasir Y Elamin, Janet Tu, George Blumenschein, Jianjun Zhang, Don Gibbons, Carl Gay, Nisha A Mohindra, Young Chae, Yanis Boumber, Joshua Sabari, Rafael Santana-Davila, Shane Rogosin, Benjamin Herzberg, Ben Creelan, Bruna Pellini, Tawee Tanvetyanon, Simon Heeke, Mike Hernandez, Jhanelle E Gray, Andreas Saltos, John V Heyma |
| First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. BMC cancer 2024 10 24 (1): 1326. Yanjuan Xiong, Lu Wang, Weihong Zhang, Yuan Meng, Yang Wang, Meng Shen, Li Zhou, Runmei Li, Yingge Lv, Shengguang Wang, Xiubao Ren, Liang L |
| Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study. Scientific reports 2024 1 14 (1): 2315. Jia Feng, Xinyi Chen, Jiayan Wei, Yiming Weng, Jingsong Wang, Tong Wang, Qibin Song, Peng M |
| Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. Journal of cancer research and clinical oncology 2024 1 150 (2): 42. Juguang Zhang, Weizhong Han, Jun Guo, Chufeng Zhang, Lijun Cao, Lixiu Peng, Xiao Han, Zhehai Wa |
| A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer. Clinical & translational immunology 2024 1 13 (1): e1483. Mingzhen Zhou, Yuncheng Jin, Sihui Zhu, Chen Xu, Lin Li, Baorui Liu, Jie Sh |
| Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). Translational lung cancer research 2024 1 12 (12): 2448-2459. Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon L |
| Efficacy and safety of chemotherapy combined with iodine-125 seed brachytherapy for intermediate and advanced oncogenic driver gene-negative non-small cell lung cancer. Brachytherapy 2025 1 24 (1): 92-102. Meng-Hua Xia, Kai-Cai Liu, Wei Zhao, Yi-Zhuang Cheng, Liang-Ping Shi, Li-Qin Bi, Xue-Ran Guo, Meng-Xia Zhang, Wei-Fu |
| RET-AREAL: a multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. Cancer letters 2025 1 217455. Xinjun Tang, Jie Hu, Renhua Guo, Yina Wang, Yu Yao, Liang Zeng, Haitao Wang, Haibo Shen, Jun Chen, Weina Huang, Lihua Liu, Ming Su, Zhuang Yu, Weidong Mao, Jinliang Wang, Haitao Tao, Guilan Dong, Chang Cai, Yupeng Xie, Tao Qu, Yan Zhang, Wei Shen, Jing Cao, Xin Cai, Wencui Kong, Xiaoxue Li, Fei Lia |
- Page last reviewed:Feb 1, 2024
- Content source: